

Seoul National University College of Medicine Alumni Association of North America, Inc.

Personalized Preventive Care for Cancer

Seoul National University College of Medicine, Korea

Daehee Kang, MD, PhD

dhkang@snu.ac.kr



Contents


- * Increased importance of personalized preventive care
 - * Aging and health
 - * Paradigm shift in medicine
 - * Precision medicine
- * Evidence of personalized preventive research on cancer
 - * Past efforts
 - * Current interests on cancer
- * Preparation for future needs
 - * Collaboration is key
 - * The next cohort for cancer in epidemiology

Part I.

Increased importance of personalized preventive care



We live LONGER!




Data from United Nations, World Population Prospects, the 2015 Revision



Aging Population

- * Extended life expectancy
 - * Average increase of 20 years during the past few decades (world)
- * Percentage of older population growing




> 20% of population over age 65




The vicious cycle will continue,

Increasing proportion of elderly population (65+): 1950-2050





Population Pyramid: Korea 2010-2060




13% of population age>65 in yr 2015 40% of population age>65 by yr 2060

Population Pyramid, from KOSIS.kr/statPpulation/main.jsp#



BUT...do we live HEALTHIER Life?



Healthy life expectancy (HALE)


* Average number of years that a person can expect to live in "full" health

Sex	Year	Life Expectancy (LE)	Healthy Life Expectancy (HALE)	Increase in LE	Increase in HALE
Men	1990	68.1	60.6	0.4	7.3
	2010	76.5	67.9	8.4	
Women	1990	76.2	67.1	6.5	5.5
	2010	82.7	72.6		

Salomon et al. Lancet. 2012



We suffer from chronic diseases!




Data from GBD 2013 @ http://viz.healthmetricsandevaluation.org/gbd-compare/




And that comes with it...

- Increased healthcare spending -



Source: OECD Health Data





Economic Loss From the Top 15 Global Causes of Death

- Impact of premature death and disability from cancer worldwide was \$895 billion in 2008
- Represents 1.5% of the world's gross domestic product (GDP)
- The economic toll from cancer is nearly 19% higher than heart disease
- The analysis did not include direct medical costs

Better, more expensive Diagnostic tools Treatment modalities

[†]Disability-adjusted Life Year

The Global Economic Cost of Cancer. American Cancer Society. 2011

Unravel the problem


- At its causal origin -

* Importance of preventive care

- * "An ounce of prevention is worth a pound of cure"
 - Benjamin Franklin

nvironmental sk factors
obalisation banisation overty ow education ress


Figure 1: The causation pathway for chronic non-communicable disease







Left shift of natural course of disease



Path to future medicine



서울대학교의과대학

Thereflices

Personalized medicine and prevention via precision and prediction


ttp:

Ordinary medicine



Governments in Action! - United States -

Obama calls for major new personalized medicine initiative





WASHINGTON (Reuters) - President Barack Obama said in his State of the Union speech on Tuesday that his administration wants to launch a new push to use personalized genetic information to help treat diseases like cancer and diabetes.

Obama urged Congress in his address to boost research funding to support new investments in "precision medicine." "I want the country that eliminated polio and mapped the human genome to lead a new era of medicine – one that

the right treatment at the right time

reverse cystic fibrosis in some patients.



U.S. President Barack Obama delivers his State of the Union address to a joint session of the U.S. Congress ...

Related Stories



2. Verily, Vanderbilt to test enrollment in U.S. Precision Medicine pilot Reuters

- Launch of a new precision medicine initiative, a \$215 million project to collect data on genomes January, 2015

Dr. Francis Collins, NIH Director:

"...empower any person, anywhere in the U.S." in what's called the **PMI Cohort Program**

"NIH will provide funding to Vanderbilt U. [for a collaborative pilot project] with Verily (former Google Life Sciences)"


Obama to ask Congress for \$309 million [in 2017 for the initiative scale up]
A massive database will track at least 1 million volunteers by 2019

February, 2016

NIH taking first steps on huge precision medicine project

AP By LAURAN NEERGAARD February 25, 2016 1:40 PM





WASHINGTON (AP) - President Barack Obama held out the promise of medical break-

http://news.yahoo.com/obama-calls-major-personalized-medicine-initiative-030325518.html http://news.yahoo.com/nih-taking-first-steps-huge-precision-medicine-project-111203692--politics.html



Dr. Francis Collins at SNUH







Precision medicine in Korea - Ministry of Health and Welfare -

Core area	Project	Department	
Infrastructure establishment for	New precision medicine cohort	Cohort	
precision medicine cohort	Enhance existing cohort and biobanks		
Prepare systemic coordination for	Standardization and linkage of genomic- medical data	Medical record and public health based big data	
precision medicine-based big data	Establishment of open data hub	Information security and standardization	
	Development of precision medicine based artificial intelligence	Public health big data	
Develop precision medicine based health services	Precision medicine based clinical experiment system	Omics	
	Development of precision medicine based healthcare service model	Mobile health care	
Improve policies and laws related to	Improvement of laws, policies, and regulations	Law/Policy	
precision medicine and develop manpower	Train professionals in the field of precision medicine	* National Cancer Center (NCC	

The use of "Korean Chip" will help realize precision medicine in Korea:

- * Genomic information on 100,000 Koreans
- Linkage with core infrastructure such as cohort, healthcare industry, electronic health records, and big data

- National Cancer Center (NCC): Large-scale cancer precision medicine cohort
 - * Genetic data of 1 million cancer patients
 - Provide basis for development of chemotherapeutic agents
 - * Big data driven prevention of cancer recurrence 국립







Precision medicine in Academia Seoul National University Bundang Hospital -



Healthcare Innovation Park (HIP) & Seoul National University Bundang Hospital (SNUBH) - Seoul National University Bundang Hospital (SNUBH) to lead Big Data-based precision medicine in Korea, a new leap since its embark as the nation's first fully digitalized, paperless hospital

- Established task force for collaborative research on precision medicine

Chul-Hee Lee, SNUBH President & CEO:


"The realization of precision medicine for each and every patient may be advanced through the integrated use of hospital database system and genomic information."

Part II.

Evidence of personalized preventive research on cancer




Today, it's all about prediction





Risk prediction using biomarkers






Seoul Breast Cancer Study (SeBCS)

Discriminative values of breast cancer risk models using genetic and non-genetic factors from Seoul Breast Cancer Study (SeBCS)

- Number of Subjects (2001-2007)
 - Cases: 4040
 - Controls: 3946
- Original papers (2003~2012)
 - SeBCS: 51 papers
 - Collaboration: 24 papers








SNUH

AMC

Borame hospital

EUMC





An example of breast cancer survival prediction

PLOS ONE

RESEARCH ARTICLE Prediction of Breast Cancer Survival Using B. Tumor subtype: rs10825036 nd Genetic Markers by Tumor A. Tumor subtype: rs166870 Discovery set **Discovery set** ob Choi^{1,2,3}, Hyuna Sung^{2,4}, Sujee Jeon³, Seokang Chung², Sue 1.52 (1.19, 1.95) Overall 1.23 (0.99, 1.51) Overall hik Han^{1,5}, Jong Won Lee⁶, Mi Kyung Kim⁷, Ji-Young Lee⁸, Keun-HR+ HER2 1.00 (0.72, 1.38) HR+ HER2-2.34 (1.64, 3.35) Ghee Han⁹, Sei-Hyun Ahn⁶, Dong-Young Noh^{1,6}, Daehee Kang^{1,2,3}* HR+ HER2+ 0.88 (0.41, 1.91) HR+ HER2 0.76 (0.39, 1.51) HR- HER2+ 1.70 (0.81, 3.59) HR- HER24 0.86 (0.50, 1.46) 1.09 (0.65, 1.83) HR- HER2-HR- HER2 2.87 (1.89, 4.34) • Overall: **Replication set Replication** set • Harrell's C_{clinical model} = 70.92% Overall 1.40 (0.96, 2.05) 1.17 (0.92, 1.48) Overall Harrell's C_{combined model} = 71.37% HR+ HER2-2.13 (1.07, 4.23) HR+ HER2 1.14 (0.79, 1.64) HR+ HER2+ 0.81 (0.38, 1.73) HR+ HER2 0.89 (0.50, 1.59) • p = 0.03HR-HER24 1.00 (0.57, 1.76) HR- HER2+ 1.04 (0.40, 2.67) 1.68 (0.97, 2.89) HR- HER2-1.40 (0.67, 2.93) HR- HER2- HR+ HER2-: Harrell's C_{clinical model} = 65.08% Combined set Combined set Harrell's C_{combined model} = 66.69% 1.20 (1.02, 1.41) Overall 1.48 (1.20, 1.83) Overall HR+ HER2 HR+ HER2-1.06 (0.83, 1.35) 2.30 (1.67, 3.15) p<0.01 0.83 (0.54, 1.30) HR+ HER2+ 0.84 (0.49, 1.45) HR+ HER2+ HR- HER2+ 0.92 (0.52, 1.36) HR- HER2+ 1.41 (0.79, 2.53) • HR- HER2-: 2.26 (1.34, 3.81) HR- HFR2-1.18 (0.77, 1.81) HR- HER2 • Harrell's C_{clinical model} = 63.26% Harrell's $C_{combined model} = 65.88\%$ p<0.01 0.23 4.34 0.24 4.23 1 1

Comparison of the **predictive powers** of disease-free survival (DFS) for breast cancer:

- Model with combined clinical (age, TNM stage, tumor subtype) and genetic variables tended to have better predictive powers overall
- Genetic factors played role in distinguishing high and low risk groups when using combined prognostic markers

Song, Kang et al., PLoS One, 2015.

Part III.

Preparation for future needs



글씨크기 🛨 🗖


1.

Ð

B 인쇄

[열린세상] 건강정보 홍수시대/강대희 서울대 의대 예방의학 학장

The speed of knowledge accumulation





Smaller world, bigger data

Wired world (the Internet)

Global transportation network

Infinite accumulation of data with database technology

More knowledge and insight




Source: IBM 2013 @ https://www-304.ibm.com/connections/blogs/ibmx86/entry/biginsights_for_big_data?lang=ko



Collaborative work is important in the future


* The art of communication and teamwork

- * With professionals from various sectors
- * Within a global setting






A next generation large genomic cohort in Korea



Taking Advantage of Korea's *Unique Environment*


- *Biennial* Health Examination *by Law* (National Health Insurance Corporation)
- National *Personal Identification* System (13-digit residence registration number)

→ Automatic Repeated Follow-up & Possible Integration to Secondary Data





HEXA (Health Examinees Study) since 2004



HEXA subjects recruit 2004-2012 (n=162,142)

- Men: Women = 2:1
- Mean age at recruitment (years)
 - Men: women = 53.7 (±8.2): 52.6(±7.6)

- Total number of questionnaires n=1,303
 - SES, Past medical history, lifestyle habits, sociopsychological factors, reproductive factors, dietary habits (including 106 SQ-FFQ)
- Clinical & physical examination

Estimated Number of Incident Cases of Selected Diseases

Disease Group	2018	2023
All-site cancer	11,749	17,800
lschemic heart disease	2,663	4,034
CVA	6,308	9,556



HEXA research activities

DOI:http://dx.doi.org/10.7314/APJCP.2015.16.4.1591 Rationale and Design of the Health Examinees Study in Korea



RESEARCH ARTICLE

What Are the Major Determinants in the Success of Smoking Cessation: Results from the Health Examinees Study

Jae Jeong Yang^{1,2}, Minkyo Song^{1,2,3}, Hyung-Suk Yoon^{1,2,3}, Hwi-Won Lee^{1,3}, Yunhee Lee^{1,3}, Sang-Ah Lee⁴, Ji-Yeob Choi^{1,3,5}, Jong-koo Lee^{6,7}, Daehee Kang^{1,2,3,5}*




Why Asia?

- * 2/3 of world's population
- * 4/5 of new cancer occurrence by 2020
- Wider distribution of exposure variables in relatively homogenous ethnic backgrounds
 - * smoking, diet, environment
- Rapid changes in certain personal habits
 - reproductive factors, urbanization, etc.





Asia Cohort Consortium (ACC)





The NEW ENGLAND JOURNAL of MEDICINE





Asia Cohort Consortium - Challenges for collaborative research -

J Epidemiol 2012;22(4):287-290 doi:10.2188/jea.JE20120024

Review Article

Asia Cohort Consortium: Challenges for Collaborative Research

Minkyo Song¹, Betsy Rolland^{2,3}, John D. Potter², and Daehee Kang^{1,4}

¹Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea ²Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washin ³Department of Human Centered Design & Engineering, College of Engineering, University of Washington, Seattle, Washin ⁴Department of Preventive Medicine, Social National University College of Medicine, Seoul, Korea

Received February 20, 2012; accepted March 12, 2012; released online May 10, 2012

ABSTRACT

In this era of chronic diseases, large studies are essential in investigating genes, environment, and interactions as disease causes, particularly when associations are important but not strong. M expansion and generalization of the results, studies should be conducted in populations outside Here, we briefly describe the Asia Cohort Consortium (ACC), a collaborative cancer cohort re was first proposed in 2004 and now involves more than 1 million healthy individuals across approximately 50 active members from Bangladesh, China, India, Japan, Korea, Malaysia, S Thailand, the United States, and elsewhere. To date, the work of the ACC includes 3 articles publis roles of body mass index, tobacco smoking, and alcohol consumption in mortality, diabetes, and c intestine. Many challenges remain, including data harmonization, resolution of ethical and legal iss of protocols for biologic samples and transfer agreements, and funding procurement.

Key words: Asia; cohort; consortium

Challenges:

- data harmonization
- resolution of ethical and legal issues
- establishment of protocols for biologic samples and transfer agreements
- funding procurement
- precise exposure assessment

INTRODUCTION

Prospective cohort studies provide the best level of observational evidence on disease causation. Furthermore, prospective cohort studies have specific strengths over clinical trials, which are often regarded as more powerful than observational studies in the hierarchy of evidence. For instance, in situations where it is unefhical to design an experimental study (eg, in situations involving exposure to tobacco, alcohol, or obesity), observational studies are the only way to undertake research. Further, unlike clinical trials, cohort studies can assess multiple outcomes for any 1 exposure or multiple exposures for a specific outcome. Chronic diseases are on the rise worldwide, and Asian countries face a growing disease burden and the many Since the completion of the Human Genome Project, epidemiologic studies encompassing genetics have prospered, and the importance of prospective cohorts has been more widely recognized.⁵ Moreover, a sufficiently large cohort or a population laboratory is essential for understanding the roles of genetic variation, environmental exposures, and the interaction between genes and exposures in the development of a disease.⁶ Analyses of gene–environment interactions in complex diseases with small interactions require even larger sample sizes to confirm associations.^{7,8} Poter has suggested that a cohort of at least 1000000 ethnically diverse individuals ("the Last Cohort") is essential to discover disease susceptibility, early-detection biomarkers, and moreprecise phenotypes.⁹



MGEL (Molecular & Genomic Epidemiology Laboratory)



THANK YOU! dhkang@snu.ac.kr

